Bright Peak is a biotech company that develops a portfolio of immunotherapies for the treatment of cancer and autoimmune diseases.
Bright Peak Therapeutics has raised $90.0M in total funding. The most recent round was Series C. The last funding was announced in June 2024.
Bright Peak Therapeutics's investors include BlackRock, Venrock, RA Capital Management, Versant Ventures, Northleaf Capital Partners.
Bright Peak Therapeutics is headquartered in Allschwil, Switzerland.
Bright Peak is a biotech company that develops a portfolio of immunotherapies for the treatment of cancer and autoimmune diseases.
Bright Peak Therapeutics is at the Series C stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Bright Peak Therapeutics — Funding & Investors." VCBacked, June 11, 2024, https://www.vcbacked.co/company/bright-peak-therapeutics. Accessed July 19, 2026.
VCBacked. (2024). Bright Peak Therapeutics — Funding & Investors. Retrieved July 19, 2026, from https://www.vcbacked.co/company/bright-peak-therapeutics
{{cite web |title=Bright Peak Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/bright-peak-therapeutics |website=VCBacked |access-date=July 19, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated